Clarity Pharmaceuticals Ltd has released a press release.
Theranostic prostate cancer trial advances to multi-dose
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Additional COBRA trial data results
- S&P DJI Announces March 2024 Quarterly Rebalance
- Initial COBRA results
- First patient dosed in Phase III prostate cancer trial
- Recruitment closes for a diagnostic Phase II trial in NETs
Later from Clarity Pharmaceuticals
- First participant treated in the last dose escalation cohort
- Trading Halt
- Clarity launches $121 million equity raise
- Investor Presentation
- Completion of Placement and Institutional Entitlement Offer
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals